Xu Weiran, Wang Kai, Gu Wenguang, Nie Xinxin, Zhang Hao, Tang Chuanhao, Lin Li, Liang Jun
Department of Oncology, Peking University International Hospital, Beijing, China.
Department of Laboratory Medicine, Beijing Haidian Hospital, Beijing, China.
Front Oncol. 2022 Mar 3;12:809068. doi: 10.3389/fonc.2022.809068. eCollection 2022.
Primary splenic angiosarcoma (PSA) is a rare malignancy with poor prognosis. At present, little study is available on immunotherapy in PSA. Here, we report a case of a patient with metastatic PSA who was treated with programmed death-1 (PD-1) inhibitors and vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors combined therapy and achieved complete response (CR). The patient was a 57-year-old woman with three liver metastases. She was treated with seven cycles of toripalimab plus anlotinib. Programmed death-ligand 1 (PD-L1) immunohistochemistry and next-generation sequencing was performed, and the PD-L1 tumor proportion score was 75%. Finally, she achieved CR after six cycles of the combined therapy regimen. No serious adverse events were detected. To the best of our knowledge, this is the first clinical evidence that anti-PD-1 plus anti-VEGF therapy might be a promising option for patients with metastatic PSA. However, more clinical trials are needed to verify this conclusion.
原发性脾血管肉瘤（PSA）是一种预后较差的罕见恶性肿瘤。目前，关于PSA免疫治疗的研究较少。在此，我们报告1例转移性PSA患者，其接受程序性死亡-1（PD-1）抑制剂与血管内皮生长因子（VEGF）酪氨酸激酶抑制剂联合治疗并获得完全缓解（CR）。该患者为一名57岁女性，有3处肝转移灶。她接受了7个周期的托瑞帕利单抗加安罗替尼治疗。进行了程序性死亡配体1（PD-L1）免疫组化和二代测序，PD-L1肿瘤比例评分达75%。最终，在联合治疗方案进行6个周期后她获得CR。未检测到严重不良事件。据我们所知，这是抗PD-1加抗VEGF治疗可能是转移性PSA患者一种有前景选择的首个临床证据。然而，需要更多临床试验来验证这一结论。
